179 related articles for article (PubMed ID: 3204664)
1. [Su-polysaccharide skin test and immunotherapy with OK-432 in postoperative gastric cancer--the effect of a splenectomy].
Saito H; Kikkawa H; Bando H; Sakatoku M; Hirano M; Tatsuzawa T
Gan No Rinsho; 1988 Nov; 34(14):1965-8. PubMed ID: 3204664
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis].
Horiuchi M; Sato K; Nakarai I; Shinoda A
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937
[TBL] [Abstract][Full Text] [Related]
3. [The Su-polysaccharide skin test in lung cancer].
Harada J; Horiguchi T; Oki K; Miyamoto H; Osada T
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2697-702. PubMed ID: 3307634
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].
Miyamoto Y; Takeshita M; Izuo M
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3229-35. PubMed ID: 3777960
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of immune status in gastric cancer using Su-Ps skin test].
Ogawa T; Yakawa H; Ogawa K; Otani Y; Kawata H; Haga S; Kasihara T; Sakakibara N
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2221-6. PubMed ID: 6385863
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of terminal-stage malignant tumors with the immunopotentiator OK-432--a comparison between SU-PS test-responder and -nonresponder patients].
Yagi Y; Yagi S; Ichiki H
Gan No Rinsho; 1987 Jun; 33(7):815-21. PubMed ID: 3302349
[TBL] [Abstract][Full Text] [Related]
7. [Role of immune skin reactions in progressive lung cancer during the administration of OK-432--relation to reactions to DNCB, PPD and Su-PS].
Katada H; Nishikawa K; Yoneda T; Kitamura H; Nakajima A; Mikami R
Gan To Kagaku Ryoho; 1987 Jan; 14(1):61-70. PubMed ID: 3026256
[TBL] [Abstract][Full Text] [Related]
8. [Relation between prognosis and the Su-PS skin reaction in patients with non-resected primary lung cancer receiving OK-432].
Nakarai I; Rikitake H; Koga T; Hayashi A; Harada Y; Takamoto M; Ishibashi T; Shinoda A; Sagawa K
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3050-7. PubMed ID: 2823723
[TBL] [Abstract][Full Text] [Related]
9. Effect of immunotherapy and spleen preservation on immunological function in patients with gastric cancer.
Okinaga K; Iinuma H; Kitamura Y; Yokohata T; Inaba T; Fukushima R
J Exp Clin Cancer Res; 2006 Sep; 25(3):339-49. PubMed ID: 17167974
[TBL] [Abstract][Full Text] [Related]
10. [Study on the preoperative adjuvant therapy of cancer--relation between serum and tumor tissue levels of UFT and OK-432 after administration, and skin reactions to Su-polysaccharide (Su-Ps)].
Kumazawa H; Ishikawa M; Rei S; Saito H
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3329-35. PubMed ID: 3120645
[TBL] [Abstract][Full Text] [Related]
11. [Clinical studies on the reaction of the skin to various doses of Su-polysaccharide in cancer patients].
Sato M; Sakai K; Kimura S; Tamaki Y; Kiyasu Y; Joko Y; Ogoshi T
Gan To Kagaku Ryoho; 1985 Feb; 12(2):245-9. PubMed ID: 3970550
[TBL] [Abstract][Full Text] [Related]
12. [Postoperative cell-mediated immunity in gastric cancer patients--with special reference to the effects of immunotherapy].
Sekizuka H; Noro K; Haruyama S; Kiribuchi Y; Hayashi F
Gan No Rinsho; 1985 Sep; 31(11):1381-6. PubMed ID: 3877822
[TBL] [Abstract][Full Text] [Related]
13. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311
[TBL] [Abstract][Full Text] [Related]
14. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
[TBL] [Abstract][Full Text] [Related]
16. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
17. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N
J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458
[TBL] [Abstract][Full Text] [Related]
18. [Non-specific immunotherapy with OK-432, streptococcus pyogenes preparation, for inoperable cancer patients of the digestive tract].
Hanaue H; Nomoto S; Yoshizaki S; Kitano Y; Miyakawa S; Horie F; Kurosawa T; Nemoto A; Yasuda H; Takada T
Nihon Gan Chiryo Gakkai Shi; 1984 Jul; 19(6):1307-14. PubMed ID: 6512346
[No Abstract] [Full Text] [Related]
19. Immunological parameters in gastric cancer patients treated with immunotherapy of streptococcal preparation OK-432.
Hanaue H; Nomoto S; Kimura T; Kutsuna T; Takeuchi T; Yoshizaki S
Keio J Med; 1982 Dec; 31(4):159-68. PubMed ID: 6985379
[No Abstract] [Full Text] [Related]
20. [Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer].
Nio Y; Tobe T
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1436-8. PubMed ID: 2586435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
